Marex Group plc priced a $500 million senior notes offering on April 16 2026, a transaction announced the following day. The notes carry a 5.680 % coupon, mature in 2031, and were issued at 100 % of principal. Goldman Sachs, Jefferies and J.P. Morgan served as joint book‑runners.
The proceeds will be deployed for working capital, incremental growth initiatives and other general corporate purposes. CEO Ian Lowitt said the debt issuance "increases our funding flexibility and further strengthens our liquidity, supporting the continued growth of our business and our ability to meet client needs. We saw a high level of investor demand, which highlights the ongoing confidence of investors in our client focused strategy, conservative capital approach and resilient liquidity profile."
Marex has a history of senior note issuances, including a $600 million 6.404 % offering due 2029 in October 2024 and a $500 million 5.829 % offering due 2028 in May 2025. The new notes reinforce the company’s strong liquidity profile and conservative capital stance, providing additional flexibility for future growth and potential acquisitions.
The company’s 2025 earnings were robust, with adjusted profit before tax rising 30 % to $418.1 million and revenue increasing 38 % to $572.1 million in the fourth quarter. The new funding will support Marex’s expansion strategy, including the scaling of its trading and technology platforms and the pursuit of strategic acquisitions.
Investors welcomed the offering, reflecting confidence in Marex’s client‑focused strategy and resilient liquidity. The high level of investor demand underscores the market’s positive view of the company’s earnings performance and growth outlook.
The offering is expected to close on April 21 2026, subject to customary closing conditions.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.